[go: up one dir, main page]

ATE275969T1 - Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort - Google Patents

Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort

Info

Publication number
ATE275969T1
ATE275969T1 AT98935097T AT98935097T ATE275969T1 AT E275969 T1 ATE275969 T1 AT E275969T1 AT 98935097 T AT98935097 T AT 98935097T AT 98935097 T AT98935097 T AT 98935097T AT E275969 T1 ATE275969 T1 AT E275969T1
Authority
AT
Austria
Prior art keywords
dexosomes
molecules
production
class
exosome
Prior art date
Application number
AT98935097T
Other languages
English (en)
Inventor
Laurence Zitvogel
Graca Raposo
Armelle Regnault
Sebastian Amigorena
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Centre Nat Rech Scient
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave, Centre Nat Rech Scient, Inst Curie filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE275969T1 publication Critical patent/ATE275969T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98935097T 1997-07-16 1998-07-03 Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort ATE275969T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9709007A FR2766205B1 (fr) 1997-07-16 1997-07-16 Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR9801437A FR2774697B1 (fr) 1997-07-16 1998-02-06 Procede de sensibilisation de cellules presentatrices d'antigene et moyens pour la mise en oeuvre du procede
PCT/FR1998/001431 WO1999003499A1 (fr) 1997-07-16 1998-07-03 Vesicule cellulaire denommee ''exosome'', leur preparation et utilisation dans la stimulation d'une reponse immunitaire

Publications (1)

Publication Number Publication Date
ATE275969T1 true ATE275969T1 (de) 2004-10-15

Family

ID=26233678

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98935097T ATE275969T1 (de) 1997-07-16 1998-07-03 Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort
AT04005883T ATE442160T1 (de) 1997-07-16 1998-07-03 Zellulares vesikel 'exosome', seine herstellung und verwendung zur stimulierung eines immunantworts

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04005883T ATE442160T1 (de) 1997-07-16 1998-07-03 Zellulares vesikel 'exosome', seine herstellung und verwendung zur stimulierung eines immunantworts

Country Status (16)

Country Link
US (2) US6685911B1 (de)
EP (2) EP1523990B1 (de)
JP (2) JP3484201B2 (de)
CN (1) CN1250285C (de)
AT (2) ATE275969T1 (de)
AU (1) AU743296B2 (de)
CA (1) CA2296750C (de)
DE (2) DE69841146D1 (de)
DK (1) DK1001806T3 (de)
EA (2) EA004300B1 (de)
ES (2) ES2331838T3 (de)
FR (2) FR2766205B1 (de)
IL (1) IL134043A0 (de)
PT (1) PT1001806E (de)
TW (1) TW592708B (de)
WO (1) WO1999003499A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510507A (ja) * 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2788780B1 (fr) * 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
AU2001259744A1 (en) * 2000-05-11 2001-11-20 Baylor Research Institute Compositions and methods for producing antigen-presenting cells
EP1299523B1 (de) * 2000-07-10 2008-12-24 Eppendorf Ag Verfahren zur modifizierung von biologischen zellen
FR2827872A1 (fr) * 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
CN100590131C (zh) 2001-08-17 2010-02-17 埃克索泰拉有限公司 用于将蛋白定向到胞外体的方法和化合物
EP1308167A1 (de) * 2001-11-06 2003-05-07 Pickl, Winfried, Ao. Univ. Prof. Dr. Antigenpräsentierende Vesikel
KR20030085659A (ko) * 2002-04-30 2003-11-07 동부한농화학 주식회사 암 치료용 엑소좀 및 그를 이용한 암 백신
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
EP2267023B1 (de) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR-Peptide und diese enthaltende Impfstoffe
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
CA2609260A1 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
US20060116321A1 (en) * 2004-07-01 2006-06-01 Robbins Paul D Immunosuppressive exosomes
DK2325305T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
WO2006093030A1 (en) 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
EP1712238A1 (de) * 2005-04-11 2006-10-18 Institut Gustave Roussy Immunogene Zusammensetzung die durch Anthracyclin getötete oder sterbende Zellen enthalt
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
CN1322115C (zh) * 2005-07-06 2007-06-20 清华大学 载有外源配体分子的胞外体及其制备方法与应用
CA2616497C (en) 2005-07-27 2016-06-07 Oncotherapy Science, Inc. Colon cancer related gene tom34
WO2007016340A2 (en) 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
WO2007127848A1 (en) 2006-04-26 2007-11-08 University Of Louisville Research Foundation, Inc Isolation of membrane vesicles from biological fluids and methods of using same
US9085778B2 (en) * 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN101085349B (zh) * 2006-06-09 2011-05-25 项雯华 囊泡导向的免疫细胞及其在制备抗肿瘤药物上的应用
WO2008108808A2 (en) * 2006-08-24 2008-09-12 Trustees Of Boston University Complexes derived from heterohybrid cells and uses thereof
KR101454287B1 (ko) 2006-10-17 2014-11-04 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
CA2676143A1 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
TWI494319B (zh) 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
CN101129405B (zh) * 2007-07-31 2011-05-11 崔澂 一种治疗习惯性流产的生物学制剂
US20110091567A1 (en) * 2007-08-06 2011-04-21 Crawford Sarah C Tissue organizing structure and therapeutic methods
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US9186405B2 (en) 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
CN104774261B (zh) 2007-08-20 2018-03-06 肿瘤疗法科学股份有限公司 Foxm1 肽和包含foxm1 肽的药剂
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
EP2072617A1 (de) 2007-12-12 2009-06-24 Trimed Biotech GmbH Verfahren zur Herstellung dendritischer Zellen
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
BRPI0919882A8 (pt) 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
SG2014013148A (en) 2009-03-18 2014-07-30 Oncotherapy Science Inc Neil3 peptides and vaccines including the same
DK2419144T3 (da) 2009-04-17 2019-10-21 Univ Oxford Innovation Ltd Sammensætning til levering af genetisk materiale
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
US8431530B2 (en) 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
CN102596177B (zh) 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
ES2362589B1 (es) 2009-12-28 2012-05-16 Centre De Recerca En Salut Internacional De Barcelona Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso.
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
RU2451292C2 (ru) * 2010-02-09 2012-05-20 Федеральное государственное унитарное предприятие "Антидопинговый центр" Способ определения эндогенных стероидов в плазме крови человека
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
TWI565473B (zh) 2010-03-11 2017-01-11 腫瘤療法 科學股份有限公司 Ｈｊｕｒｐ胜肽與含此胜肽之疫苗
TW201627003A (zh) 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
JP6025707B2 (ja) * 2010-04-06 2016-11-16 エクソサイト セラピューティクス ピーティイー リミテッド 癌を治療する方法
CN109432126B (zh) * 2011-03-11 2022-06-14 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物
WO2012135844A2 (en) 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
UA113413C2 (uk) 2011-08-12 2017-01-25 Онкотерапі Саєнс, Інк. Пептид mphosph1 та вакцина, що його містить
CN102302784B (zh) 2011-08-22 2012-12-05 湖北盛齐安生物科技有限公司 一种肿瘤化疗药物制剂及其制备方法
IN2014CN03922A (de) 2011-10-28 2015-09-04 Oncotherapy Science Inc
CN104080911A (zh) 2011-11-30 2014-10-01 不来梅大学 miRNA在胎盘组织中的表达
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
CN103446580B (zh) * 2012-05-31 2016-08-03 湖北盛齐安生物科技有限公司 一种肿瘤疫苗及其制备方法
US10231997B2 (en) 2012-08-15 2019-03-19 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
CN105264092B (zh) 2013-03-15 2019-02-22 得克萨斯州大学系统董事会 用于诊断和疗法的外来体中的miRNA生物发生
EP3888640B1 (de) 2013-06-05 2025-09-17 Reverse Bioengineering, Inc. Zusammensetzungen und verfahren zur induzierten geweberegeneration in säugerspezies
US10987432B2 (en) 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
WO2015048844A1 (en) * 2013-10-02 2015-04-09 Xosoma Pty Ltd A method of producing exosomes
US9921223B2 (en) * 2013-12-04 2018-03-20 Board Of Regents, The University Of Texas System Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10624929B2 (en) 2014-05-18 2020-04-21 Children's Medical Center Corporation Methods and compositions relating to exosomes
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
DK3178837T3 (da) 2014-08-04 2021-03-15 Oncotherapy Science Inc Urlc10-afledt peptid og vaccine, der indeholder dette
SG11201700839SA (en) 2014-08-04 2017-03-30 Oncotherapy Science Inc Cdca1-derived peptide and vaccine containing same
CN111925413B (zh) 2014-08-04 2025-04-18 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
CN105031661A (zh) * 2015-05-28 2015-11-11 杭州优玛达生物科技有限公司 生物膜、具有生物膜性的闭合结构或细胞区室作为基因转染试剂或者基因治疗试剂的应用
CN104984359A (zh) * 2015-05-28 2015-10-21 杭州优玛达生物科技有限公司 生物膜、具有生物膜性的闭合结构或细胞区室作为疫苗载体或免疫调节剂的应用
BR112017026467A2 (pt) 2015-06-10 2018-09-11 Univ Texas uso de exossomos para o tratamento de doença
EP3115058A1 (de) 2015-07-09 2017-01-11 Institut Gustave Roussy Immunogene peptide von prä-prokalzitonin
IL257335B (en) 2015-08-12 2022-08-01 Oncotherapy Science Inc Depdc1-derived peptide and vaccine containing same
US11242365B2 (en) 2015-10-08 2022-02-08 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
JP2018536438A (ja) 2015-12-07 2018-12-13 バイオタイム，インコーポレーテッド 多様な多能性幹細胞から誘導された褐色脂肪細胞の再誘導のための方法
EP3393511A1 (de) * 2015-12-21 2018-10-31 La Jolla Institute for Allergy and Immunology Nutzung des immungedächtnisses aus impfstoffen für häufige kinderkrankheiten zur krankheitsbekämpfen
EP3402901A1 (de) * 2016-01-11 2018-11-21 Dixon, Janette Verfahren zur bestimmung von tumorphänotypen
AU2017226956A1 (en) * 2016-03-03 2018-10-11 Institut Gustave Roussy PTPS-based vaccines against cancer
WO2017177204A1 (en) * 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US20200046779A1 (en) 2016-10-13 2020-02-13 Vbc Holdings Llc Anti-inflammatory exosomes from inflamed cells or tissues
CN110072534A (zh) 2016-10-13 2019-07-30 Vbc控股有限责任公司 外泌体的医学应用
US20200046766A1 (en) * 2016-10-13 2020-02-13 Vbc Holdings Llc Cancer stem cell exosomes
US10040831B2 (en) 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
KR101862502B1 (ko) * 2017-01-02 2018-05-29 성균관대학교산학협력단 재구성 인공 암세포, 이의 제조 방법, 및 이를 포함하는 항암 조성물
JP6923875B2 (ja) * 2017-01-27 2021-08-25 東亞合成株式会社 腫瘍細胞のｃｄ４７発現を抑制するための薬剤組成物およびその利用
KR101944665B1 (ko) * 2017-02-24 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 만성폐쇄성기도질환 진단 방법
US10815520B2 (en) 2017-04-07 2020-10-27 University Of Louisville Research Foundation, Inc. Nanovesicles, methods, and systems for diagnosis and prognosis of cancer
KR101999818B1 (ko) * 2017-07-26 2019-07-12 ㈜로제타엑소좀 소수성 상호작용을 이용한 세포밖 소포체의 분리방법
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CN109576219A (zh) * 2017-09-29 2019-04-05 河南省肿瘤医院 一种用于扩增t淋巴细胞的纳米级膜性囊泡的制备方法
BR112020013405A2 (pt) * 2018-01-25 2020-12-01 Acm Biolabs Pte Ltd. polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
CN110123842B (zh) * 2018-02-09 2022-03-15 上海市第六人民医院 一种外泌体缓释体系及其构建方法与应用
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN110876734A (zh) * 2018-09-06 2020-03-13 杨昆德 包含胞外囊泡的制剂、用以制备该制剂的方法及其用途
IT201800009235A1 (it) 2018-10-08 2020-04-08 Universita' Degli Studi Di Palermo Procedimento per la sintesi di esosomi contenenti proteine da shock termico e loro uso per il trattamento della atrofia muscolare e della cachessia
EP3917515A1 (de) 2019-01-29 2021-12-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Behandlung des verursachenden mittels in der adhäsiogenese
CN116785416B (zh) * 2023-06-14 2025-01-14 首都医科大学附属北京佑安医院 一种树突状细胞外泌体肝癌疫苗制备方法
EP4537820A1 (de) 2023-10-13 2025-04-16 Institut Gustave-Roussy Verbindung und kombinationen mit dieser verbindung zur verbesserung der immunreaktion
EP4574155A1 (de) 2023-12-22 2025-06-25 Christine Süßmuth Moleküle zur verwendung bei der zellregeneration und -regeneration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510507A (ja) * 1995-08-03 1999-09-14 リュークスウニベルジテート トゥ ライデン 細胞由来の抗原提示小胞
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
EP2058389B1 (de) * 1997-10-27 2016-05-18 Rockefeller University Definiertes Reifungsmedium für dendritische Zellen enthaltend TNF-alpha, IL-1beta, IL-6
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma

Also Published As

Publication number Publication date
FR2774697A1 (fr) 1999-08-13
EA002827B1 (ru) 2002-10-31
US7625573B2 (en) 2009-12-01
DK1001806T3 (da) 2005-01-24
JP2003125762A (ja) 2003-05-07
FR2766205B1 (fr) 2002-08-30
DE69841146D1 (de) 2009-10-22
US6685911B1 (en) 2004-02-03
JP3484201B2 (ja) 2004-01-06
PT1001806E (pt) 2004-12-31
ES2227863T3 (es) 2005-04-01
JP2000512161A (ja) 2000-09-19
CN1265038A (zh) 2000-08-30
FR2774697B1 (fr) 2004-04-30
EA004300B1 (ru) 2004-02-26
EA200200517A1 (ru) 2002-10-31
EA200000130A1 (ru) 2000-08-28
JP3691468B2 (ja) 2005-09-07
CA2296750A1 (fr) 1999-01-28
AU8446498A (en) 1999-02-10
US20040028692A1 (en) 2004-02-12
EP1523990B1 (de) 2009-09-09
ES2331838T3 (es) 2010-01-18
EP1523990A1 (de) 2005-04-20
DE69826288D1 (de) 2004-10-21
ATE442160T1 (de) 2009-09-15
AU743296B2 (en) 2002-01-24
EP1001806B1 (de) 2004-09-15
TW592708B (en) 2004-06-21
CA2296750C (fr) 2012-09-18
WO1999003499A1 (fr) 1999-01-28
DE69826288T2 (de) 2005-11-03
CN1250285C (zh) 2006-04-12
FR2766205A1 (fr) 1999-01-22
IL134043A0 (en) 2001-04-30
EP1001806A1 (de) 2000-05-24

Similar Documents

Publication Publication Date Title
ATE275969T1 (de) Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort
ATE319477T1 (de) Antigen presentierende bläschen, die von zellen ableiten
EP2341072A3 (de) Verfahren zur Gewinnung aktivierter T-Zellen und antigen-inkubierte antigenpräsentierende Zellen
HK1041433A1 (zh) 人工抗原特异性细胞和相关方法
AU6597998A (en) HLA-A2.1 binding peptides and their uses
BR9610802A (pt) Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
AU6195398A (en) HLA binding peptides and their uses
EP0922758A3 (de) Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
ATE268812T1 (de) Methode und zusammensetzungen zum erlangen reifer dendritischer zellen
CA2214649A1 (en) Antigen presenting system and methods for activation of t-cells
ATE72104T1 (de) Rollstuhl.
EP2377548A3 (de) Isolierung und/oder Konservierung von dendritischen Zellen als Prostata-Krebs-Immuntherapie
CA2258878A1 (en) Liposomal influenza vaccine composition and method
ATE296313T1 (de) Hla-a2.1 bindende peptide und deren verwendung
EP1917970A3 (de) Hla-bindende Peptide und ihre Verwendungen
CA2182889A1 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
AU5646101A (en) Immunotherapeutic methods and compositions
EP0531401A4 (en) Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
AU4577899A (en) Hla binding peptides and their uses
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
Miller et al. Use of positively selected Lyt-2+ mouse splenocytes to examine interleukin-2 secretion in responses to alloantigens and to TNP-modified syngeneic cells
DE69434946D1 (de) Verwendung von MHC-Xenoantigenes zur Herstellung eines Arzneimittels für eine therapeutische Behandlung von Krebs
GENG et al. Research advance on exosome-based cancer immunotherapy
ES295589Y (es) Reposabrazos con atril antipanico para butacas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001806

Country of ref document: EP

REN Ceased due to non-payment of the annual fee